Literature DB >> 16951946

The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement.

Benan Musellim1, Hande Ikitimur, Hafize Uzun, Gul Ongen.   

Abstract

We aimed to assess the plasma oxidant and antioxidant levels in systemic sclerosis (SS) patients with interstitial lung involvement. Twenty-seven female SS patients and 17 healthy female volunteers were included in the study. Plasma levels of oxidants and antioxidants levels were studied of two groups. The median oxidant and antioxidant levels in study and control groups were, MDA 5.2 +/- 0.4/3.7 +/- 0.5 nmol/ml (P < 0.001), NO 45.4 +/- 3.7/34.2 +/- 2.9 nmol/l (P < 0.001), SOD 25.6 +/- 2.3/24.6 +/- 2.0 U/ml (P > 0.05), catalase 99.9 +/- 9.9/140.0 +/- 10.0 U/ml (P < 0.001), vitamin E 20.5 +/- 1.3/22.6 +/- 2.0%mg (P < 0.001), vitamin C 70.6 +/- 8.7/83.5 +/- 7.3 mg/dl (P < 0.001), respectively. There was also no correlation between plasma levels of oxidants-antioxidants levels and disease duration, duration of pulmonary signs, pulmonary function test values, HRCT scores in SS patients (P > 0.05). In our study, the oxidant burden in SS patients with interstitial lung involvement was found to be increased; however no correlation was detected between the severity of lung involvement and oxidant-antioxidant levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951946     DOI: 10.1007/s00296-006-0184-6

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  31 in total

1.  A micromethod for assay of total tocopherols in blood serum.

Authors:  M L QUAIFE; N S SCRIMSHAW; O H LOWRY
Journal:  J Biol Chem       Date:  1949-10       Impact factor: 5.157

2.  Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis.

Authors:  A M Cantin; R C Hubbard; R G Crystal
Journal:  Am Rev Respir Dis       Date:  1989-02

3.  Improved superoxide dismutase assay for clinical use.

Authors:  L Sun; T E Peterson; M L McCormick; L W Oberley; J W Osborne
Journal:  Clin Chem       Date:  1989-06       Impact factor: 8.327

4.  Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis.

Authors:  T Yamamoto; I Katayama; K Nishioka
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

5.  A simple method for clinical assay of superoxide dismutase.

Authors:  Y Sun; L W Oberley; Y Li
Journal:  Clin Chem       Date:  1988-03       Impact factor: 8.327

6.  Oxidative stress in Systemic Sclerosis.

Authors:  G Simonini; M M Cerinic; S Generini; M Zoppi; M Anichini; C Cesaretti; A Pignone; F Falcini; T Lotti; M Cagnoni
Journal:  Mol Cell Biochem       Date:  1999-06       Impact factor: 3.396

7.  Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma.

Authors:  C M Stein; S B Tanner; J A Awad; L J Roberts; J D Morrow
Journal:  Arthritis Rheum       Date:  1996-07

8.  Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon.

Authors:  C P Denton; T D Bunce; M B Dorado; Z Roberts; H Wilson; K Howell; K R Bruckdorfer; C M Black
Journal:  Rheumatology (Oxford)       Date:  1999-04       Impact factor: 7.580

9.  High resolution computed tomography in early scleroderma lung disease.

Authors:  J H Warrick; M Bhalla; S I Schabel; R M Silver
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

10.  Increased nitric oxide in exhaled air in patients with systemic sclerosis.

Authors:  I Fajac; A Kahan; C J Menkès; J F Dessanges; J Dall'Ava-Santucci; A T Dinh-Xuan
Journal:  Clin Exp Rheumatol       Date:  1998 Sep-Oct       Impact factor: 4.473

View more
  3 in total

1.  Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis.

Authors:  Alexandra Balbir-Gurman; Yolanda Braun-Moscovici; Vladimir Livshitz; Daniel Schapira; Doron Markovits; Alexander Rozin; Tatiana Boikaner; A Menahem Nahir
Journal:  Clin Rheumatol       Date:  2007-03-31       Impact factor: 2.980

2.  Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis.

Authors:  Esen Savas; Nur Aksoy; Yavuz Pehlivan; Zeynel Abidin Sayiner; Zeynel Abidin Oztürk; Suzan Tabur; Mustafa Orkmez; Ahmet Mesut Onat
Journal:  Wien Klin Wochenschr       Date:  2014-05-14       Impact factor: 1.704

3.  Serum antioxidant status in patients with systemic sclerosis.

Authors:  Iffat Hassan; Peerzada Sajad; Sabiya Majid; Tehseen Hassan
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.